Cue Biopharma, Inc. (CUE) Stock Price & Analysis

Cue Biopharma, Inc. (CUE) rose 1.58% to USD 27.88 as of September 8, 2026 at 16:19 UTC, according to Nexqual real-time market data.

CUE last closed at USD 27.88; the session ranged USD 25.62–27.88 on volume of 79,689 shares. Market capitalization is —, with a 52-week range of USD 4.98–45.5 (NCM). Source: Nexqual, September 8, 2026 at 16:19 UTC.

Key Statistics (as of September 8, 2026 at 16:19 UTC)

Technical Analysis (CUE)

Nexqual's technical model rates CUE "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 16:19 UTC.

From Cue Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• CUE-100 Series Historically, we primarily focused our resources on the development of our CUE-100 series for oncology, namely the CUE-101 and CUE-102 drug product candidates, which are representative of our approach to selectively activate targeted CD8+ T cells against cancer, both of which have been licensed to ImmunoScape Pte.
• Plan of Operation Our approach to developing precision immunotherapies has yielded a growing portfolio of novel proteins with the potential to address multiple unmet needs across autoimmune diseases.
• The percentage of such proceeds that we are required to pay Einstein ranges from the low to mid-teens, depending on how far we have developed a Licensed Product before we enter into an agreement relating to the Licensed Product.
• We believe that our approach provides us with a superior competitive advantage and differentiation, with a potentially first-in-class, masked TGF-b and IL-2 designed to address the underlying mechanism of disease by rebalancing the Treg and effector cell ratio . 9   Many of our competitors have greater financial, technical and human resources than we do.

Partnerships

• Under our Collaboration and License Agreement with IMSCP, IMSCP is developing a novel Seed-and-Boost immunotherapy that combines our clinically validated Immuno-STAT T-cell engagers, the CUE-100 series, with IMSCP's proprietary tumor-specific T cell receptors, or TCRs.
• Our Collaboration Agreement with LG Chem On November 6, 2018, we entered into a Collaboration, License and Option Agreement, as amended from time to time, or the LG Chem Collaboration Agreement, with LG Chem Ltd., or LG Chem, pertaining to the development of CUE-101 and CUE-102 Immuno-STATs in Australia and in certain countries in Asia, or the LG Chem Territory.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:19 UTC. This page is informational and not investment advice.